In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

publication date

  • June 18, 2019